A collaborative research team including Cornell scientists has discovered that trametinib, an FDA-approved drug for melanoma in humans, can significantly treat oral squamous cell carcinomas in dogs. This cancer, which often leads to disfiguring surgeries and reduced quality of life, has historically been challenging to manage, especially when metastasized. The research found the drug effective in tumor growth inhibition in mouse models and dogs. Notably, one dog's tumor nearly vanished within weeks, marking a major advancement in veterinary oncology. The treatment is relatively affordable, typically costing $100 to $200 monthly, depending on the dog's size.
The drug, trametinib, targets a downstream component of the RAS signaling pathway, which regulates cell growth and has implications for several cancers in humans and animals.
We are already getting calls and emails from colleagues and from dog owners from all over the world, indicating the excitement around this breakthrough treatment.
I’ve never seen results like that in mice before...being on a project that made it to the clinic and seeing the tumor nearly vanish was delightfully surprising.
A month’s worth of treatment with trametinib is relatively inexpensive, costing between $100 to $200 based on the dog's size.
Collection
[
|
...
]